What Woodford worries?

A trio of U.K. life science investors don’t expect the recent lackluster performance of Neil Woodford to weigh on local biotechs looking to raise money.

The high profile investor’s largest fund, Woodford Equity Income Fund, saw its assets under management fall 17% from £10 billion ($13 billion) to £8.3 billion ($11.2 billion) in 2H17. More than half of the losses were due to redemptions, including a £450 million ($636.1 million) withdrawal by Jupiter Asset Management...